‘Absolute Disaster’: Pharma Whistleblower Slams Popular Weight-Loss Drug

Pharmaceutical consultant-turned-whistleblower Calley Means told Tucker Carlson that Ozempic, the hot new weight-loss drug, poses…

Children's Health Defense

By The Defender Staff

A pharmaceutical industry whistleblower warned that Ozempic, the new diabetes and obesity drug sold by Novo Nordisk, poses a potential safety “disaster.”

Calley Means, founder of health tech firm TrueMed, during the Feb. 2 episode of “The Tucker Carlson Encounter” cited numerous reported side effects — including gastrointestinal issues and suicidal thoughts — of the popular weight-loss drug.

Means also cited reports of lingering issues after people stopped using the drug.

Ozempic is the brand name for semaglutide, an injectable drug that reduces appetite and causes weight loss in people who are obese or overweight.

Means, co-author of the book, “Good Energy: The Surprising Link Between Metabolism and Limitless Health,” also argued drugs like Ozempic fail to address the current metabolic health crisis in the U.S., which is rooted in poor nutrition and lifestyle choices.

While Wall Street cheers Novo Nordisk’s projected $1 trillion stock value by 2030, Means contended, “Obesity is not an Ozempic deficiency” but rather a symptom of declining metabolic health that prescription drugs fail to remedy.

According to Means, surging obesity rates have created perverse financial motivations that prioritize lifelong pharmaceutical use over preventative care.

Fundamental healthcare reforms are needed, he argued, to reverse the spikes in lifestyle diseases. “This miracle drug is too good to be true,” he said…